GO:1900119 positive regulation of execution phase of apoptosis: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900119 describes any process that activates or increases the frequency, rate or extent of the execution phase of apoptosis, the final irreversible stage of programmed cell death.
• The execution phase is driven by effector caspases such as caspase-3 and caspase-7, which cleave structural and repair proteins after mitochondrial outer membrane permeabilization.
• Positive regulation of this phase can occur through Bcl-2 family imbalance, p53 target activation, or death-receptor signaling, and is experimentally separable from earlier apoptotic steps.
• Assays for phosphatidylserine externalization and DNA fragmentation can be differentially regulated by caspases, so execution-phase readouts must be chosen carefully.
• Dysregulated execution-phase apoptosis contributes to cancer chemoresistance, atherosclerosis, and leukemic cell death, making it a key therapeutic and research target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate regulators of GO:1900119 in relevant cell types.
Description
GO:1900119, positive regulation of execution phase of apoptosis, is a Gene Ontology biological process term that captures any process which activates or increases the frequency, rate or extent of the execution phase of apoptosis. Apoptosis is a genetically controlled form of programmed cell death essential for development, tissue homeostasis, and elimination of damaged cells, and its execution phase represents the point at which the cell commits irreversibly to dismantling itself. Understanding what positively regulates this phase is therefore central to cancer biology, immunology, and developmental genetics. The execution phase is classically defined by the activation of effector caspases, which cleave hundreds of substrates and produce the biochemical and morphological hallmarks of apoptosis, including DNA fragmentation and phosphatidylserine externalization. However, these hallmarks are not always coupled, and their regulation can differ between cell types and stimuli, which makes the positive regulation of this phase a distinct and experimentally tractable research problem. Studies in human T cells, breast cancer cells, leukemic cells, and atherosclerotic plaques have identified multiple positive regulators, including Bcl-2 family proteins, p53AIP1, and death-receptor-associated signaling components. The nematode Caenorhabditis elegans has provided conserved genetic evidence for the core execution machinery, reinforcing the evolutionary depth of this process. For researchers, GO:1900119 provides a precise annotation target for functional genomics, CRISPR screening, and drug-response studies aimed at modulating cell death.
positive regulation of execution phase of apoptosis At A Glance
| GO ID | GO:1900119 |
|---|---|
| GO term | positive regulation of execution phase of apoptosis |
| Ontology | biological_process |
| Synonym | activation of execution phase of apoptosis; up regulation of execution phase of apoptosis; up-regulation of execution phase of apoptosis; upregulation of execution phase of apoptosis |
| Major function | Activates or increases the frequency, rate or extent of the execution phase of apoptosis |
| Biological context | Terminal, irreversible stage of programmed cell death driven by effector caspases and Bcl-2 family signaling |
| Representative regulators | Bcl-2 family proteins, p53AIP1, caspase substrates, death-receptor pathway components |
| Disease relevance | Cancer chemoresistance, leukemic cell death, atherosclerosis, and developmental cell death |
| Experimental readouts | Caspase activity, DNA fragmentation, phosphatidylserine externalization, mitochondrial permeabilization |
What Is GO:1900119?
In plain terms, GO:1900119 refers to any biological process that turns up or accelerates the final, irreversible stage of apoptosis, the execution phase. The QuickGO definition states: Any process that activates or increases the frequency, rate or extent of execution phase of apoptosis. This is a biological_process term, meaning it describes a coordinated set of molecular events rather than a single molecule or location. It is the positive counterpart to negative regulation of execution phase of apoptosis and is distinct from upstream initiation or decision-phase terms. Synonyms include activation of execution phase of apoptosis, up regulation of execution phase of apoptosis, up-regulation of execution phase of apoptosis, and upregulation of execution phase of apoptosis.
Why Is positive regulation of execution phase of apoptosis Important in Cell Biology?
Positive regulation of the execution phase of apoptosis is important because it determines whether a cell completes programmed death or survives, directly influencing cancer treatment response, immune homeostasis, and tissue remodeling. Because the execution phase is the point of no return, factors that positively regulate it are attractive therapeutic targets and mechanistic biomarkers.
• Defines the terminal commitment step of apoptosis, making it a decisive node for cell-fate control.
• Effector caspase activation and substrate cleavage are the core events positively regulated in this phase.
• Bcl-2 family balance, including nuclear and mitochondrial Bcl-2 pools, modulates execution-phase sensitivity in T cells.
• p53AIP1 up-regulation precedes apoptosis in breast cancer cells, linking p53 signaling to execution-phase activation.
• Death-receptor-directed antibodies can trigger execution-phase apoptosis in human leukemic cells.
• Apoptosis-linked gene 2 is downregulated in human atherosclerotic plaques, implicating execution-phase regulation in vascular disease.
• Caspase-dependent DNA fragmentation and phosphatidylserine externalization can be uncoupled, requiring careful assay design.
• Conserved genetic pathways in C. elegans provide a framework for dissecting execution-phase regulators.
• Cartilage and chondrocyte apoptosis assays illustrate tissue-specific detection of execution-phase events.
• CRISPR-based models enable causal testing of positive regulators in disease-relevant cells.
What Happens During positive regulation of execution phase of apoptosis?
Commitment and mitochondrial permeabilization
In simple terms: The cell decides to die and opens the mitochondrial gate that releases death-promoting factors.
Positive regulation of the execution phase often begins with mitochondrial outer membrane permeabilization, which releases pro-apoptotic factors and commits the cell to death. In T cell apoptosis, nuclear and mitochondrial Bcl-2 pools are differentially regulated, indicating that subcellular localization of Bcl-2 family proteins influences execution-phase progression. This step is a key control point because it determines whether effector caspases will be activated downstream.
Effector caspase activation
In simple terms: Executioner enzymes are switched on to start cutting the cell's key proteins.
Effector caspases such as caspase-3 and caspase-7 are activated during the execution phase and cleave structural, signaling, and repair proteins. Caspase activity is a defining biochemical feature of the execution phase, and its positive regulation increases the rate and extent of substrate cleavage. Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases shows that caspase-dependent and caspase-independent readouts can diverge.
Substrate cleavage and DNA fragmentation
In simple terms: The activated enzymes cut DNA and other targets, producing the classic signs of cell death.
Once effector caspases are active, they cleave substrates that lead to DNA fragmentation and other hallmarks of apoptosis. In anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells, phosphatidylserine externalization and DNA fragmentation were differentially regulated by caspases, showing that positive regulation of the execution phase can be assay-dependent. Detection of apoptosis in cartilage and isolated chondrocytes further illustrates tissue-specific execution-phase readouts.
p53-linked amplification
In simple terms: A stress-response protein boosts the death program before the execution phase fully engages.
Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells, providing evidence that p53 target activation can positively regulate the execution phase. This links DNA-damage and cell-cycle stress responses to the terminal death machinery.
Death-receptor-triggered execution
In simple terms: External death signals can push cells directly into the execution phase.
CD176 antibody induces apoptosis in human leukemic cells through mechanisms that engage the execution phase. This demonstrates that positive regulation of execution-phase apoptosis can be initiated from the cell surface and propagated to caspase activation.
Conserved developmental execution
In simple terms: The same death program is used during normal development in simple animals.
Programmed cell death during Caenorhabditis elegans development provides conserved genetic evidence for the core execution machinery and its positive regulators. This model organism has been instrumental in defining how execution-phase apoptosis is activated and executed.
Key Genes Involved in GO:1900119 positive regulation of execution phase of apoptosis
The following genes and proteins have been experimentally linked to positive regulation of the execution phase of apoptosis in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCL2 | Anti-apoptotic Bcl-2 family protein; nuclear and mitochondrial pools differentially regulated in T cell apoptosis | Determines execution-phase sensitivity and mitochondrial permeabilization threshold |
| CASP3 | Effector caspase that cleaves substrates during the execution phase | Core execution-phase marker and target for functional assays |
| CASP7 | Effector caspase activated during the execution phase | Contributes to substrate cleavage and DNA fragmentation |
| TP53 | Tumor suppressor upstream of p53AIP1 and apoptosis | Links stress signaling to execution-phase activation |
| TP53AIP1 | p53-regulated pro-apoptotic protein up-regulated before apoptosis in MCF-7 cells | Positive regulator of execution-phase onset in breast cancer models |
| ALG2 | Apoptosis-linked gene 2, downregulated in human atherosclerotic plaques | Implicated in vascular cell death and plaque biology |
| CED-3 | C. elegans caspase ortholog required for programmed cell death | Conserved execution-phase caspase in developmental apoptosis |
| CED-4 | C. elegans Apaf-1-like adaptor for caspase activation | Core execution-phase activator in developmental models |
| EGL-1 | C. elegans BH3-only protein promoting cell death | Positive regulator of developmental execution-phase apoptosis |
| CD176 antigen | Surface target whose antibody induces leukemic cell apoptosis | Model for death-receptor-triggered execution-phase activation |
| Caspase substrates | Structural and repair proteins cleaved during execution | Readouts for execution-phase progression |
| Phosphatidylserine | Membrane lipid externalized during apoptosis | Assay readout for execution-phase regulation |
| DNA fragmentation machinery | Caspase-dependent and independent DNA cleavage | Distinguishes execution-phase pathways |
| Chondrocyte apoptosis markers | Execution-phase readouts in cartilage | Tissue-specific model for apoptosis detection |
| Bcl-2 family regulators | Balance of pro- and anti-apoptotic proteins | Modulates mitochondrial permeabilization and execution |
| Death-receptor signaling components | Transmit external death signals to caspases | Therapeutic target in leukemic cells |
How Is positive regulation of execution phase of apoptosis Regulated?
Positive regulation of the execution phase of apoptosis is controlled by the balance of Bcl-2 family proteins, effector caspase activation, and upstream stress signals such as p53. Nuclear versus mitochondrial Bcl-2 localization can differentially regulate T cell apoptosis, indicating compartment-specific control. p53AIP1 up-regulation precedes apoptosis in breast cancer cells, showing that p53-dependent transcription can positively regulate the execution phase. Death-receptor signaling, as shown with CD176 antibody in leukemic cells, provides an external route to execution-phase activation. Caspase-dependent and caspase-independent pathways can be differentially engaged, so regulation must be assessed with multiple readouts.
positive regulation of execution phase of apoptosis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53AIP1 | Breast cancer chemosensitivity | MCF-7 knockout and overexpression models |
| BCL2 | T cell apoptosis and immune homeostasis | T cell lines with tagged knock-in of BCL2 |
| ALG2 | Atherosclerotic plaque biology | Vascular smooth muscle cell knockout models |
| CASP3 | Leukemic cell death and chemotherapy response | Leukemia cell lines with caspase-3 point mutation |
| CD176 antigen | Leukemic cell apoptosis | Antibody-treated leukemic cell models |
Cancer and chemoresistance
Positive regulation of the execution phase of apoptosis is central to cancer chemotherapy, because many drugs ultimately rely on effector caspase activation to kill tumor cells. In human MCF-7 breast cancer cells, roscovitine-induced p53AIP1 up-regulation precedes apoptosis, linking cell-cycle stress to execution-phase activation. In human leukemic cells, CD176 antibody triggers apoptosis through mechanisms that engage the execution phase, suggesting a therapeutic route for death-receptor-directed agents. Conversely, failure to positively regulate this phase can contribute to chemoresistance.
Atherosclerosis and vascular disease
Western array analysis of human atherosclerotic plaques revealed downregulation of apoptosis-linked gene 2, implicating altered execution-phase regulation in vascular lesion biology. This suggests that positive regulation of execution-phase apoptosis may influence plaque stability and vascular cell turnover.
Developmental and tissue-specific cell death
Programmed cell death during Caenorhabditis elegans development depends on conserved execution-phase regulators, providing a genetic framework for understanding human disease mechanisms. Detection of apoptosis in cartilage and isolated chondrocytes demonstrates that execution-phase readouts are relevant to musculoskeletal tissue biology.
From positive regulation of execution phase of apoptosis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for execution-phase apoptosis? | CRISPR knockout in disease-relevant cell lines |
| Does a specific caspase catalytic residue drive substrate cleavage? | Point-mutation knock-in of caspase active-site residue |
| Does a p53 target amplify execution-phase onset? | Knock-in of tagged p53AIP1 for localization studies |
| Does overexpression of an anti-apoptotic Bcl-2 family member block execution? | Overexpression cell model with mitochondrial readouts |
| Can death-receptor signaling be redirected to execution-phase apoptosis? | Antibody-treated leukemic cells with caspase assays |
| Is execution-phase regulation conserved in development? | C. elegans genetic models |
How to Study the positive regulation of execution phase of apoptosis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Caspase activity assay | Effector caspase enzymatic activity | Quantifying execution-phase activation |
| Immunoblotting for caspase substrates | Substrate cleavage during execution | Confirming execution-phase progression |
| DNA fragmentation assay | Caspase-dependent DNA cleavage | Distinguishing execution-phase pathways |
| Phosphatidylserine externalization assay | Membrane changes during apoptosis | Detecting early execution-phase events |
| Mitochondrial permeabilization assay | Release of pro-apoptotic factors | Assessing Bcl-2 family regulation |
| Western array profiling | Expression changes in disease tissue | Identifying execution-phase regulators in atherosclerosis |
| Chondrocyte apoptosis detection | Execution-phase readouts in cartilage | Tissue-specific apoptosis studies |
| p53AIP1 up-regulation analysis | p53 target induction before apoptosis | Breast cancer chemosensitivity studies |
Caspase activity and substrate cleavage assays
Effector caspase activity is a defining readout of the execution phase, and assays measuring caspase-3 and caspase-7 activity can quantify positive regulation. Substrate cleavage products can be detected by immunoblotting to confirm execution-phase progression.
DNA fragmentation and phosphatidylserine externalization
DNA fragmentation and phosphatidylserine externalization are classic execution-phase readouts, but they can be differentially regulated by caspases, so both should be measured when assessing positive regulation. Detection of apoptosis in cartilage and isolated chondrocytes provides a tissue-specific example of these methods.
Mitochondrial and Bcl-2 family analysis
Mitochondrial permeabilization and Bcl-2 family localization can be assessed to determine how positive regulation of the execution phase is initiated. Differential regulation of nuclear and mitochondrial Bcl-2 in T cell apoptosis highlights the value of compartment-specific analysis.
Expression and up-regulation studies
Up-regulation of pro-apoptotic proteins such as p53AIP1 can be measured by immunoblotting or transcript profiling before the onset of apoptosis. Western array analysis of human atherosclerotic plaques illustrates how expression profiling can identify execution-phase regulators in disease tissue.
How CRISPR Can Be Used to Study GO:1900119 positive regulation of execution phase of apoptosis
Knockout
CRISPR knockout of candidate genes such as TP53AIP1, BCL2, or CASP3 can test whether they are required for positive regulation of the execution phase of apoptosis. Knockout models in MCF-7 or leukemic cell lines allow caspase activity and DNA fragmentation to be measured after apoptotic stimuli.
Point Mutation
Point-mutation knock-in of catalytic residues in effector caspases can dissect which enzymatic activities are required for execution-phase progression. Such models help distinguish caspase-dependent from caspase-independent execution events.
Knock-in
Tagged knock-in of BCL2 or TP53AIP1 enables localization and interaction studies during execution-phase apoptosis. This is particularly useful for separating nuclear and mitochondrial pools of Bcl-2 family proteins.
Overexpression
Overexpression of anti-apoptotic Bcl-2 family members or pro-apoptotic p53AIP1 can test sufficiency for blocking or promoting the execution phase. Overexpression models complement knockout studies by establishing gain-of-function effects.
How EDITGENE Supports positive regulation of execution phase of apoptosis Research
Researchers studying positive regulation of execution phase of apoptosis-related genes often need to determine whether a candidate gene is causally involved in caspase activation, DNA fragmentation, or mitochondrial permeabilization. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible testing of such hypotheses in disease-relevant backgrounds.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of execution phase of apoptosis research.
Frequently Asked Questions About positive regulation of execution phase of apoptosis
What is GO:1900119 positive regulation of execution phase of apoptosis?
GO:1900119 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of the execution phase of apoptosis.
What genes are involved in positive regulation of execution phase of apoptosis?
Genes and proteins implicated include BCL2, CASP3, CASP7, TP53, TP53AIP1, ALG2, and conserved C. elegans regulators such as CED-3 and CED-4.
How is the execution phase of apoptosis activated?
It is activated by mitochondrial outer membrane permeabilization and effector caspase activation, which cleave substrates and lead to DNA fragmentation.
What is the difference between execution phase and initiation phase of apoptosis?
The execution phase is the terminal, irreversible stage marked by effector caspase activity and substrate cleavage, whereas initiation involves upstream death signals and decision-phase regulation.
Which caspases execute apoptosis?
Effector caspases such as caspase-3 and caspase-7 execute apoptosis by cleaving structural and repair proteins.
How do you measure positive regulation of execution phase of apoptosis?
Common readouts include caspase activity assays, DNA fragmentation assays, phosphatidylserine externalization, and mitochondrial permeabilization assays.
Is p53 involved in the execution phase of apoptosis?
p53 signaling can positively regulate the execution phase, as shown by roscovitine-induced p53AIP1 up-regulation preceding apoptosis in MCF-7 cells.
What diseases are linked to dysregulated execution-phase apoptosis?
Cancer chemoresistance, leukemic cell death, and atherosclerosis have been linked to altered execution-phase regulation.
Can CRISPR be used to study positive regulation of execution phase of apoptosis?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate regulators in relevant cell types.
What model organisms are used to study execution-phase apoptosis?
Caenorhabditis elegans is a key model for conserved execution-phase apoptosis, alongside human and rodent cell lines.
Conclusion
GO:1900119 positive regulation of execution phase of apoptosis defines the processes that accelerate or enhance the terminal, irreversible stage of programmed cell death. The cited literature shows that this phase is controlled by Bcl-2 family balance, effector caspases, p53 targets such as p53AIP1, and death-receptor signaling, with disease relevance in cancer, leukemia, and atherosclerosis. Careful assay design is essential because caspase-dependent DNA fragmentation and phosphatidylserine externalization can be differentially regulated. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide robust tools for causal dissection of this process.
References
- 1. Scheel-Toellner D et al.. 2008. Differential regulation of nuclear and mitochondrial Bcl-2 in T cell apoptosis.. Apoptosis 13(1):109-17 PMID: 17957472
- 2. Guchelaar HJ et al.. 1997. Apoptosis: molecular mechanisms and implications for cancer chemotherapy.. Pharm World Sci 19(3):119-25 PMID: 9259027
- 3. Wesierska-Gadek J et al.. 2005. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells.. Mol Cancer Ther 4(1):113-24 PMID: 15657359
- 4. Martinet W et al.. 2003. Western array analysis of human atherosclerotic plaques: downregulation of apoptosis-linked gene 2.. Cardiovasc Res 60(2):259-67 PMID: 14613855
- 5. Conradt B et al.. 2016. Programmed Cell Death During Caenorhabditis elegans Development.. Genetics 203(4):1533-62 PMID: 27516615
- 6. Yi B et al.. 2011. Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells.. Int J Oncol 38(6):1565-73 PMID: 21455576
- 7. Huigsloot M et al.. 2001. Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases in anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells.. Biochem Pharmacol 62(8):1087-97 PMID: 11597577
- 8. D'Lima DD et al.. 2004. Detection of apoptosis in cartilage in situ and in isolated chondrocytes.. Methods Mol Med 100:275-90 PMID: 15280601
